Venetoclax (Venclexta) in combination with obinutuzumab has been added to the PBS as a first line therapy in patients with CLL who are unfit for conventional chemotherapy. The PBS listing follows trial data including from the CLL-14 study published last year in the NEJM which found venetoclax and obinutuzumab was associated with longer PFS than ...
PBS listing for new front line non-chemo treatment for CLL
By Mardi Chapman
7 Dec 2020